A special inspection to crack down on medical corruption has come.

Recently, a judgment of the Chinese Referee's Paper Network showed that the former director of a third-class hospital was sentenced for bribery. according to the
judgment, Wang Jianmin, the former president of a third-class hospital in Sichuan Province, used his position to obtain benefits for others in the procurement of medicines and equipment between 2005 and 2019, receiving property of 2.417204 million yuan, was sentenced to four years' imprisonment and a fine of 400,000 yuan.
meanwhile, 620,000 yuan of his illegal income was handed over to the State Treasury (paid), and 116,000 U.S. dollars (RMB821,1524 million) of his house and parking space was recovered and turned over to the State Treasury.
Saibai Blue according to public information combing found that only in the first half of 2020, a number of hospital directors, department heads have been dropped, most of the reasons investigated around drugs, medical supplies and other fields to receive kickbacks or use their authority to intervene in infrastructure projects.
, in recent years, from the grass-roots community to the Sanjia Hospital, the director of the department because of bribery is not uncommon.
according to incomplete statistics, there will be more than 300 hospital director in 2019, including 18 in Sanjia Hospital.
Previously, there have been prosecution case officers publicly said that medical corruption involving many departments, personnel, up to the Director, the President, down to the Chief of the Pharmaceutical Section, chief of the Finance Section, procurement staff, medical personnel, often investigated a number of cases, seized a number of people led to dozens or even dozens of people.
so we can also see that in recent years in the medical anti-corruption work, medical personnel are the focus of inspection.
on the issue of medical corruption, the Central Commission for Discipline Inspection in the State Health Commission discipline inspection and supervision team responsible for the said that will increase pressure conduction, in accordance with the "who is in charge, who is responsible for" and "the management industry must manage the conduct of the wind" requirements, around the field of health care outstanding issues, in-depth special rectification.
Marketing costs remain high, pharmaceutical companies were names recently, a number of listed pharmaceutical companies received the Shenzhen Stock Exchange issued the 2019 annual report inquiry letter, asking for separate explanation of the proportion of academic promotion fees to sales costs, sales costs rate is at a reasonable level in the industry, and whether there is commercial bribery or to facilitate commercial bribery.
Of the 306 pharmaceutical-related listed companies, 39 will have revenues of more than $10 billion in 2019, including 8 with sales expenses of more than 5 billion yuan and 33 pharmaceutical companies with sales expenses of more than 50% in 2019, according to Minet data.
overall figures, the growth rate is lower than in the past, but there are still problems of high sales costs for pharmaceutical companies.
exactly is the cost of selling pharmaceutical companies? As the Accounting Standards for Enterprises do not specify this, the breakdown of sales expenses of listed pharmaceutical companies is different.
Common accounts are employee compensation, marketing expenses, conference fees, business (entertainment) expenses, travel expenses, advertising (propaganda) expenses and transportation expenses, enterprises can adjust their own accounts according to the actual situation, some enterprises for the purpose of sales channels, as well as rental fees, depreciation fees and other sales of construction equipment costs.
from the listed pharmaceutical company sales costs composition, its list of more names, including sales staff compensation, day-to-day administrative costs, marketing and academic promotion.
, prescription drug companies to market costs, conference fees, consulting fees are the main items of sales costs.
An ombudsman of the Ministry of Finance has previously said that although a large number of sales costs are actually occurring, but a large part of the money is only withdrawn in the name of sales costs to transfer funds to third-party intermediary companies, most of these companies in the face of consulting services companies, no actual business, has become a gray area for enterprises to withdraw funds.
at present, the sales and sales costs of pharmaceutical companies have become the main cost component of the "factory price" of drugs, and in the pharmaceutical supply chain, the circulation link accounts for the majority of drug operating costs.
cases, sales costs have swallowed up the original profits of pharmaceutical companies, even exceeding their costs, creating a pathological growth mechanism.
therefore, the sales costs of pharmaceutical companies are also the focus of the relevant departments in recent years.
, the Ministry of Finance and the Health Insurance Administration joined forces to check the financial problems of 77 pharmaceutical companies, with a focus on sales costs.
the requirements of the Ministry of Finance, the contents of the inspection include compliance with accounting laws and regulations, financial accounting systems, internal control norms, etc., as well as the authenticity of the costs, costs and revenues of pharmaceutical companies.
, especially sales expense authenticity, cost authenticity, revenue authenticity, sales rebates and other issues.
in the two-vote system, medical insurance fee control and other policy background, the relevant departments of the drug companies sales costs are still under strict investigation.
Strictly check rebates, inspection and covert visit group set out recently, the National Health Council issued "on the issuance of the 2020 medical industry style construction work special action plan notice" (National Health Office Medical Letter (2020) No. 592).
According to the notice, the special rectification period is July-December 2020 and is divided into three stages: the education and self-examination phase (July 2020): health and health administrative departments and medical institutions at all levels to organize working meetings to mobilize and deploy widely.
the central publicity and rectification phase (August-November 2020): special inspections and covert visits continue to be carried out throughout the country.
assessment and summary phase (December 2020): the local area of the special rectification work to summarize and assess the situation.
from the time point of view, has now entered August, I believe that some areas of the special inspection team should have set out.
The State Health And Health Commission has made it clear that it will carry out special governance to combat the collection of kickbacks by practitioners of medical institutions, and investigate and punish the acts of medical institutions and their practitioners who use their practice to obtain improper benefits and receive kickbacks.
In this regard, for medical institutions, the focus is on combating the following six acts: 1, medical institutions practitioners accept drugs, medical devices, medical and health materials and other pharmaceutical products production, business enterprises or distributors in various names, forms of rebate behavior; 4. The act of medical institutions and their employees publishing medical advertisements in violation of regulations and participating in the marketing activities of pharmaceutical products, food products, health care products and other commodities; 5, medical personnel use any means and means to count the quantity information of individual physicians and clinical departments on the use of drugs and medical supplies for commercial purposes, and to facilitate the statistics of pharmaceutical marketers; 6, medical personnel in violation of regulations to purchase, sell, use drugs, medical and health materials and other pharmaceutical products.
pharmaceutical enterprises, serious investigation and punishment of pharmaceutical products production, operating enterprises distribution personnel in medical institutions in violation of marketing practices.
shall focus on examining the illegal sale of medicines and medical devices to medical personnel by pharmaceutical products production, business enterprises or distribution personnel in areas such as outpatient clinics, inpatient departments and pharmacies of medical institutions, and conduct commercial negotiations.
with the departure of the secret visit group, medical anti-corruption will continue to escalate.
once the doctor and the dean are checked, will the pharmaceutical companies involved be safe and sound? Obviously not.
in this round of inspection covert visits, the pharmaceutical companies should also check their own self-correction in advance.
compliance is the hard truth for long-term development.
original title: strict investigation of kickbacks, secret visit group set out.